Clinical Trial

DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr

Name: DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr — clinical trial record (NCT04106115)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: DURANCE

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

DURANCE is a two part, phase Ib/II, multi-centre study to assess the safety and activity of S-488210/S-488211 in combination with durvalumab, in patients with non-muscle invasive bladder cancer (NMIBC).

Trial Details

NCT Number	NCT04106115
Lead Sponsor	University College, London Collaborators: AstraZeneca, Shionogi
Conditions	Bladder Cancer
Enrollment	52 participants
Start Date	2022-03-25
Primary Completion	2027-03-30 (estimated)
Study Completion	2032-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-11